Table 2.
Loss of p21 in colon cancer and patient mortality
| Total N | Colon cancer-specific mortality | Overall mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Deaths/ person- years |
Univariate HR (95% CI) |
HR adjusted for stage and LINE-1 (95% CI) |
Multivariate HR (95% CI) |
Deaths/ person- years |
Univariate HR (95% CI) |
HR adjusted for stage and LINE-1 (95% CI) |
Multivariate HR (95% CI) |
||
| p21-expressing cases | 138 (21%) | 38/1103 | 1 (referent) | 1 (referent) | 1 (referent) | 63/1103 | 1 (referent) | 1 (referent) | 1 (referent) |
| p21-lost cases | 509 (79%) | 124/4193 | 0.85 (0.59-1.22) | 0.67 (0.45-0.99) | 0.58 (0.38-0.89) | 216/4193 | 0.90 (0.68-1.19) | 0.81 (0.60-1.08) | 0.71 (0.51-0.98) |
| P value | 0.37 | 0.047 | 0.013 | 0.46 | 0.072 | 0.035 | |||
The multivariate, stage-matched (stratified) Cox regression model included age, year of diagnosis, sex, family history of colorectal cancer, body mass index (BMI), tumor location, grade, KRAS, BRAF, PIK3CA, p53, cyclin D1, LINE-1 methylation, microsatellite instability (MSI), and CpG island methylator phenotype (CIMP).
CI, confidence interval; HR, hazard ratio.